Overview of Dr. Tamari
Dr. Roni Tamari is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and NYC Health + Hospitals / Jacobi. She received her medical degree from Ben Gurion University of the Negev and has been in practice 15 years. She is one of 497 doctors at Memorial Sloan Kettering Cancer Center and one of 15 doctors at NYC Health + Hospitals / Jacobi who specialize in Oncology. She has more than 90 publications and over 500 citings.
Office
530 East 74th Street
New York, NY 10021
Education & Training
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Hematology and Medical Oncology, 2008 - 2011- Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2004 - 2008
Ben Gurion University of the NegevClass of 2002
Certifications & Licensure
FL State Medical License 2022 - Present
NJ State Medical License 2020 - 2025
NY State Medical License 2007 - 2025- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse Start of enrollment: 2013 Dec 01
- T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia Start of enrollment: 2018 May 09
- Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis. Start of enrollment: 2018 Aug 28
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Correction: Placental expanded mesenchymal-like cells (PLX-R18) for poor graft function after hematopoietic cell transplantation: A phase I study.Joseph P McGuirk, Leland Metheny 3rd, Luis Pineiro, Mark Litzow, Scott D Rowley
Bone Marrow Transplantation. 2024-12-03 - Emapalumab as salvage therapy for adults with malignancy-associated hemophagocytic lymphohistiocytosis.William T Johnson, Zachary D Epstein-Peterson, Nivetha Ganesan, Timothy Pak, Tiffany Chang
Haematologica. 2024-09-01 - 8 citationsDonor-Derived Malignancy and Transplantation Morbidity: Risks of Patient and Donor Genetics in Allogeneic Hematopoietic Stem Cell Transplantation.Lacey S Williams, Kirsten M Williams, Nancy Gillis, Kelly Bolton, Frederik Damm
Transplantation and Cellular Therapy. 2024-03-01
Lectures
- Hematologic Malignancies Arising in Patients with Germ Cell Tumors: Secondary Somatic Differentiation of Hematopoietic Malignancies from Germ Cell Precursors2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- A Simple Geriatric Vulnerability Index for Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Double-Unit Cord Blood (CB) Transplantation with Haplo-Identical CD34+ Cells (haplo-dCBT) May Speed Neutrophil Recovery Although Successful Bridging Is Contingent on C...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Protecting Patients with Blood Cancers from COVID-19September 17th, 2021- Ruxolitinib Pre-, During- and Post-HSCT for Patients with Primary or Secondary MyelofibrosisFebruary 9th, 2018
- Risk Stratification in Myelofibrosis: Which Model Should You Use?July 6th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
